Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

Guardado en:
Detalles Bibliográficos
Autores principales: Jean Galtier, Camille Alric, Emilie Bérard, Thibaut Leguay, Suzanne Tavitian, Audrey Bidet, Eric Delabesse, Jean Baptiste Rieu, Jean-Philippe Vial, François Vergez, Nicolas Lechevalier, Isabelle Luquet, Emilie Klein, Anne-Charlotte de Grande, Audrey Sarry, Arnaud Pigneux, Christian Récher, Sarah Bertoli, Pierre-Yves Dumas
Formato: article
Lenguaje:EN
Publicado: Nature Publishing Group 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/f96185a801b446e9a88718b9b046da3a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f96185a801b446e9a88718b9b046da3a
record_format dspace
spelling oai:doaj.org-article:f96185a801b446e9a88718b9b046da3a2021-11-14T12:43:28ZIntermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes10.1038/s41408-021-00551-y2044-5385https://doaj.org/article/f96185a801b446e9a88718b9b046da3a2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41408-021-00551-yhttps://doaj.org/toc/2044-5385Jean GaltierCamille AlricEmilie BérardThibaut LeguaySuzanne TavitianAudrey BidetEric DelabesseJean Baptiste RieuJean-Philippe VialFrançois VergezNicolas LechevalierIsabelle LuquetEmilie KleinAnne-Charlotte de GrandeAudrey SarryArnaud PigneuxChristian RécherSarah BertoliPierre-Yves DumasNature Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBlood Cancer Journal, Vol 11, Iss 11, Pp 1-4 (2021)
institution DOAJ
collection DOAJ
language EN
topic Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Jean Galtier
Camille Alric
Emilie Bérard
Thibaut Leguay
Suzanne Tavitian
Audrey Bidet
Eric Delabesse
Jean Baptiste Rieu
Jean-Philippe Vial
François Vergez
Nicolas Lechevalier
Isabelle Luquet
Emilie Klein
Anne-Charlotte de Grande
Audrey Sarry
Arnaud Pigneux
Christian Récher
Sarah Bertoli
Pierre-Yves Dumas
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
format article
author Jean Galtier
Camille Alric
Emilie Bérard
Thibaut Leguay
Suzanne Tavitian
Audrey Bidet
Eric Delabesse
Jean Baptiste Rieu
Jean-Philippe Vial
François Vergez
Nicolas Lechevalier
Isabelle Luquet
Emilie Klein
Anne-Charlotte de Grande
Audrey Sarry
Arnaud Pigneux
Christian Récher
Sarah Bertoli
Pierre-Yves Dumas
author_facet Jean Galtier
Camille Alric
Emilie Bérard
Thibaut Leguay
Suzanne Tavitian
Audrey Bidet
Eric Delabesse
Jean Baptiste Rieu
Jean-Philippe Vial
François Vergez
Nicolas Lechevalier
Isabelle Luquet
Emilie Klein
Anne-Charlotte de Grande
Audrey Sarry
Arnaud Pigneux
Christian Récher
Sarah Bertoli
Pierre-Yves Dumas
author_sort Jean Galtier
title Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
title_short Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
title_full Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
title_fullStr Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
title_full_unstemmed Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
title_sort intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
publisher Nature Publishing Group
publishDate 2021
url https://doaj.org/article/f96185a801b446e9a88718b9b046da3a
work_keys_str_mv AT jeangaltier intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT camillealric intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT emilieberard intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT thibautleguay intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT suzannetavitian intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT audreybidet intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT ericdelabesse intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT jeanbaptisterieu intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT jeanphilippevial intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT francoisvergez intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT nicolaslechevalier intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT isabelleluquet intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT emilieklein intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT annecharlottedegrande intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT audreysarry intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT arnaudpigneux intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT christianrecher intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT sarahbertoli intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
AT pierreyvesdumas intermediatedosecytarabineorstandarddosecytarabineplussingledoseanthracyclineaspostremissiontherapyinolderpatientswithacutemyeloidleukemiaimpactonhealthcareresourceconsumptionandoutcomes
_version_ 1718429084104523776

Ejemplares similares